TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce
that for the third consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national
survey of Canadian physicians and pharmacists.
The 2018 OTC Recommendations Survey was conducted by RK Insights and the following publications within
the EnsembleIQ Healthcare Group: Pharmacy Practice + Business, The Medical Post, Profession
Santé, CanadianHealthcareNetwork.ca, and ProfessionSanté.ca. This annual survey was conducted online between August 2017 and
October 2017 with Canadian physicians and pharmacists. In total, 1,649 surveys were completed by pharmacists and 955 surveys were
completed by physicians. FeraMAX® was named by both pharmacists and physicians surveyed as the most recommended iron
supplement brand to Canadian patients.
“We are very pleased with the 2018 survey results and the #1 recommendation for our FeraMAX® brand
for the third consecutive year,” commented Mr. René Goehrum, President and CEO of BioSyent. “We are thankful that Canadian
healthcare providers have recognized the benefits of FeraMAX® in the treatment and prevention of iron deficiency anaemia
and continue to recommend FeraMAX® to their patients.”
About FeraMAX®
FeraMAX® 150 is an oral iron supplement indicated for the prevention and treatment of iron deficiency
anaemia. This non-ionic polysaccharide-iron complex formulation reduces adverse gastrointestinal side effects commonly experienced
with other iron formulations. A Vegan Certified formulation of FeraMAX® 150 is also available in Canadian pharmacies and
provides an iron therapy option for vegans, vegetarians, and patients with other dietary restrictions. FeraMAX® Powder,
based upon the same innovative non-ionic polysaccharide-iron complex technology found in FeraMAX® 150, is available in a
pleasant tasting, dissolvable powder for pediatric patients.
For more information on FeraMAX®, please visit www.feramax.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that
have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital
and international business units.
As of the date of this press release, the Company has 14,509,095 common shares issued and outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit
www.tmxmoney.com.
This press release may contain information or statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or
outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not
limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining
regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: investors@biosyent.com
Web: www.biosyent.com
